U.S. flag

An official website of the United States government

NM_000059.4(BRCA2):c.509T>C (p.Phe170Ser) AND Hereditary cancer-predisposing syndrome

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
May 19, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002335979.2

Allele description [Variation Report for NM_000059.4(BRCA2):c.509T>C (p.Phe170Ser)]

NM_000059.4(BRCA2):c.509T>C (p.Phe170Ser)

Gene:
BRCA2:BRCA2 DNA repair associated [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
13q13.1
Genomic location:
Preferred name:
NM_000059.4(BRCA2):c.509T>C (p.Phe170Ser)
HGVS:
  • NC_000013.11:g.32326275T>C
  • NG_012772.3:g.15796T>C
  • NM_000059.4:c.509T>CMANE SELECT
  • NM_001406719.1:c.509T>C
  • NM_001406720.1:c.509T>C
  • NM_001406721.1:c.509T>C
  • NM_001406722.1:c.140T>C
  • NP_000050.2:p.Phe170Ser
  • NP_000050.3:p.Phe170Ser
  • NP_001393648.1:p.Phe170Ser
  • NP_001393649.1:p.Phe170Ser
  • NP_001393650.1:p.Phe170Ser
  • NP_001393651.1:p.Phe47Ser
  • LRG_293t1:c.509T>C
  • LRG_293:g.15796T>C
  • LRG_293p1:p.Phe170Ser
  • NC_000013.10:g.32900412T>C
  • NM_000059.3:c.509T>C
  • NR_176251.1:n.708T>C
Protein change:
F170S
Molecular consequence:
  • NM_000059.4:c.509T>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001406719.1:c.509T>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001406720.1:c.509T>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001406721.1:c.509T>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001406722.1:c.140T>C - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV002642462Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)		Uncertain significance
(May 19, 2022) 		germlineclinical testing

Citation Link

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From Ambry Genetics, SCV002642462.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

The p.F170S variant (also known as c.509T>C), located in coding exon 5 of the BRCA2 gene, results from a T to C substitution at nucleotide position 509. The phenylalanine at codon 170 is replaced by serine, an amino acid with highly dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024